These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 18528690)
1. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Gao Y; Zhang LR; Fu Q Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690 [TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738 [TBL] [Abstract][Full Text] [Related]
3. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. Li YP; Zhang LR; Jia M; Hu XJ J Clin Pharmacol; 2011 Feb; 51(2):181-8. PubMed ID: 20519697 [TBL] [Abstract][Full Text] [Related]
4. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340 [TBL] [Abstract][Full Text] [Related]
5. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Wang A; Yu BN; Luo CH; Tan ZR; Zhou G; Wang LS; Zhang W; Li Z; Liu J; Zhou HH Eur J Clin Pharmacol; 2005 Feb; 60(12):843-8. PubMed ID: 15650881 [TBL] [Abstract][Full Text] [Related]
6. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823 [TBL] [Abstract][Full Text] [Related]
7. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O; Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115 [TBL] [Abstract][Full Text] [Related]
8. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285 [TBL] [Abstract][Full Text] [Related]
9. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491 [TBL] [Abstract][Full Text] [Related]
11. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621 [TBL] [Abstract][Full Text] [Related]
13. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965 [TBL] [Abstract][Full Text] [Related]
15. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570 [TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW; Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001 [TBL] [Abstract][Full Text] [Related]
17. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Shabana MF; Mishriki AA; Issac MS; Bakhoum SW Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857 [TBL] [Abstract][Full Text] [Related]
18. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734 [TBL] [Abstract][Full Text] [Related]
19. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554 [TBL] [Abstract][Full Text] [Related]
20. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]